GoodRx Holdings, Inc. (NASDAQ:GDRX) Short Interest Update

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 7,930,000 shares, a growth of 6.6% from the November 30th total of 7,440,000 shares. Currently, 9.1% of the shares of the company are short sold. Based on an average daily trading volume, of 1,350,000 shares, the short-interest ratio is currently 5.9 days.

Hedge Funds Weigh In On GoodRx

Several institutional investors have recently bought and sold shares of the business. nVerses Capital LLC bought a new position in shares of GoodRx in the third quarter worth about $33,000. Plato Investment Management Ltd acquired a new stake in shares of GoodRx in the second quarter valued at approximately $43,000. EP Wealth Advisors LLC bought a new position in GoodRx in the 3rd quarter worth approximately $73,000. Sanctuary Advisors LLC acquired a new position in GoodRx during the 3rd quarter worth $85,000. Finally, Dark Forest Capital Management LP bought a new position in GoodRx in the 2nd quarter valued at $86,000. Institutional investors own 63.77% of the company’s stock.

Wall Street Analysts Forecast Growth

GDRX has been the topic of several recent research reports. Citigroup decreased their price objective on GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Morgan Stanley decreased their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Barclays dropped their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Finally, Mizuho began coverage on shares of GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.37.

GoodRx Price Performance

Shares of NASDAQ:GDRX traded up $0.14 during trading on Wednesday, reaching $4.65. The stock had a trading volume of 1,136,538 shares, compared to its average volume of 1,417,009. The stock has a market capitalization of $1.77 billion, a PE ratio of -155.00, a P/E/G ratio of 3.54 and a beta of 1.29. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx has a 52 week low of $4.09 and a 52 week high of $9.26. The business’s 50-day moving average price is $5.01 and its 200 day moving average price is $6.75.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.